There are a number of biotech catalyst events left in November, including FDA/PDUFA events, data readouts, and biomedical meetings. See the table below highlighting the events in the next 2 weeks:
PRVB - Provention Bio
PRVB's asset PRV-031 (Teplizumab) has a PDUFA target action date of November 17, 2022 for the treatment of Type 1 diabetes. The teplizumab BLA previously received a CRL on July 6, 2021 and the BLA was resubmitted on February 22, 2022. The BLA was accepted in March and a PDUFA date was originally set for August 17, 2022, but was extended to 11/17/2022 in June 2022. Positive data had previously been reported throughout 2020 and 2021 and an AdComm meeting for the first submission had a vote of 10-7 that the benefits outweighed the risks of teplizumab. Sanofi will be joining forces with Provention Bio to bring Teplizumab to market.
Don't miss next weeks Catalyst Watchlist. Get our free weekly newsletter
*We never send you spam - unsubscribe anytime